OKYO Pharma Limited (OKYO)
NASDAQ: OKYO · Real-Time Price · USD
1.385
+0.005 (0.36%)
At close: Sep 25, 2026, 4:00 PM EDT
1.380
-0.005 (-0.36%)
After-hours: Sep 25, 2026, 7:30 PM EDT
OKYO Pharma Ratios and Metrics
Market cap in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Quarter | Current | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 25, 2026 | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 |
| 72 | 84 | 78 | 75 | 96 | 43 | 39 | 35 | 40 | 50 | 59 | |
Market Cap Growth (YoY) | -8.91% | 96.04% | 100.10% | 117.95% | 143.18% | -12.97% | -33.86% | -33.89% | 35.30% | - | - |
Enterprise Value | 52 | 80 | 76 | 74 | 95 | 42 | 38 | 34 | 38 | 48 | 57 |
Last Close Price | 1.38 | 1.61 | 2.07 | 2.00 | 2.57 | 1.27 | 1.15 | 1.02 | 1.19 | 1.49 | 1.77 |
Price Ratios
Fiscal Quarter | Current | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 25, 2026 | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 |
PB Ratio | 5.87 | 6.85 | 6.31 | -22.02 | -28.16 | -7.77 | -7.01 | -4.78 | -5.47 | -8.42 | -10.01 |
P/TBV Ratio | 5.87 | 6.85 | 6.31 | - | - | - | - | - | - | - | - |
Financial Efficiency
Fiscal Quarter | Current | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 25, 2026 | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 |
Debt / Equity Ratio | - | - | - | -0.05 | -0.05 | - | - | 0 | 0 | - | - |
Net Debt / Equity Ratio | -1.67 | -1.67 | -1.67 | 1.18 | 1.18 | 0.28 | 0.28 | 0.14 | 0.14 | 0.14 | 0.14 |
Net Debt / EBITDA Ratio | 2.42 | 2.42 | 2.79 | 0.65 | 0.61 | 0.22 | 0.18 | 0.10 | 0.08 | 0.05 | 0.05 |
Net Debt / FCF Ratio | 3.47 | 3.47 | 4.56 | 1.30 | 1.64 | 0.86 | 0.66 | 0.34 | 0.16 | 0.09 | 0.08 |
Quick Ratio | 2.40 | 2.40 | 2.40 | 0.53 | 0.53 | 0.37 | 0.37 | 0.25 | 0.25 | 0.19 | 0.19 |
Current Ratio | 2.43 | 2.43 | 2.43 | 0.58 | 0.58 | 0.40 | 0.40 | 0.28 | 0.28 | 0.21 | 0.21 |
Return on Equity (ROE) | -263.78% | -263.78% | -199.88% | - | - | - | - | - | - | - | - |
Return on Assets (ROA) | -43.09% | -43.09% | -37.40% | -104.63% | -111.63% | -169.87% | -208.94% | - | - | -291.87% | -298.20% |
Return on Capital Employed (ROCE) | -68.90% | -68.90% | -59.80% | 183.10% | 195.40% | 127.80% | 157.20% | 143.30% | 180.60% | 267.90% | 273.70% |
Yields
Fiscal Quarter | Current | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 25, 2026 | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 |
Earnings Yield | -12.36% | -10.59% | -8.71% | -6.13% | -4.84% | -10.92% | -19.78% | -30.97% | -34.78% | -33.98% | -28.41% |
FCF Yield | -8.20% | -7.03% | -5.81% | -4.12% | -2.55% | -4.21% | -6.11% | -8.52% | -15.71% | -19.16% | -17.41% |
Buyback Yield / Dilution | 5.40% | 5.40% | -8.26% | -24.46% | -29.20% | -34.57% | -35.66% | -36.97% | -34.52% | -31.84% | -30.38% |